Stephens & Co. Reiterates Overweight on 10x Genomics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Mason Carrico has reiterated an Overweight rating on 10x Genomics (NASDAQ:TXG) and maintained a $30 price target.
October 10, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stephens & Co. has reiterated its Overweight rating on 10x Genomics, maintaining a $30 price target, indicating confidence in the company's potential for growth.
The reiteration of an Overweight rating and maintenance of a $30 price target by Stephens & Co. suggests a positive outlook for 10x Genomics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100